Status:
UNKNOWN
Treatment of Knee Osteoarthritis (KOA) by Injection of Autologous Adipose-derived Vascular Matrix Components (SVF) Into Joint Cavity
Lead Sponsor:
Xijing Hospital
Conditions:
Knee Osteoarthritis
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
The purpose of this study was to analyze and study the efficacy and safety of autologous adipose-derived vascular matrix components (SVF) in patients with knee osteoarthritis before and after treatmen...
Eligibility Criteria
Inclusion
- The age range is 20-70 years old
- Patients with unilateral or bilateral knee degenerative inflammation (KOA) with Kellgren-lawrence rating of level 3 or lower
- The physical health status is mainly in the ASA grade Ⅰ, Ⅱ and Ⅲ
- Subjects had no active tumors, no active inflammation, no treponema pallidum, HIV, hepatitis B virus, or hepatitis C virus
- The subject shall provide the physical examination report of knee X-ray examination, MRI examination and other items
Exclusion
- Patients with nonunion or displaced fractures around defective cartilage
- Pregnant or lactating women
- Autoimmune disease
- Subjects with diabetes (exceptions are patients whose blood sugar levels remain within the normal range and diabetes has not caused other complications)
- The patients had severe neurological diseases affecting the evaluation of postoperative results
Key Trial Info
Start Date :
March 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06109220
Start Date
March 30 2023
End Date
December 30 2024
Last Update
October 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital
Xi'an, Shannxi, China, 710034